TMDX Quote, Financials, Valuation and Earnings

Electromed has a net margin of 3.88% compared to TransMedics Group's net margin of 10.05%. TransMedics Group's return on equity of 19.83% beat Electromed's return on equity of 15.62%.

TransMedics Group has a consensus price target of $102.00, signalling upside risk potential of 62.94%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 10.74%. Given that TransMedics Group has higher upside potential than Electromed, analysts believe TransMedics Group is more attractive than Electromed.

TransMedics Group has a beta of 2.058, which suggesting that the stock is 105.81% more volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

TransMedics Group quarterly revenues are $108.8M, which are larger than Electromed quarterly revenues of $14.7M. TransMedics Group's net income of $4.2M is higher than Electromed's net income of $1.5M. Notably, TransMedics Group's price-to-earnings ratio is 66.60x while Electromed's PE ratio is 41.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 5.40x versus 4.66x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 3.88% compared to TransMedics Group's net margin of -10.5%. TransMedics Group's return on equity of 19.83% beat Myomo's return on equity of -84.04%.

TransMedics Group has a consensus price target of $102.00, signalling upside risk potential of 62.94%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 19.42%. Given that TransMedics Group has higher upside potential than Myomo, analysts believe TransMedics Group is more attractive than Myomo.

TransMedics Group has a beta of 2.058, which suggesting that the stock is 105.81% more volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

TransMedics Group quarterly revenues are $108.8M, which are larger than Myomo quarterly revenues of $9.2M. TransMedics Group's net income of $4.2M is higher than Myomo's net income of -$966.4K. Notably, TransMedics Group's price-to-earnings ratio is 66.60x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 5.40x versus 9.38x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 3.88% compared to TransMedics Group's net margin of -11.97%. TransMedics Group's return on equity of 19.83% beat Inari Medical's return on equity of -17.68%.

TransMedics Group has a consensus price target of $102.00, signalling upside risk potential of 62.94%. On the other hand Inari Medical has an analysts' consensus of $66.59 which suggests that it could grow by 23.01%. Given that TransMedics Group has higher upside potential than Inari Medical, analysts believe TransMedics Group is more attractive than Inari Medical.

TransMedics Group has a beta of 2.058, which suggesting that the stock is 105.81% more volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

TransMedics Group quarterly revenues are $108.8M, which are smaller than Inari Medical quarterly revenues of $153.4M. TransMedics Group's net income of $4.2M is higher than Inari Medical's net income of -$18.4M. Notably, TransMedics Group's price-to-earnings ratio is 66.60x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 5.40x versus 5.46x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 3.88% compared to TransMedics Group's net margin of -67.31%. TransMedics Group's return on equity of 19.83% beat Stereotaxis's return on equity of -108.68%.

TransMedics Group has a consensus price target of $102.00, signalling upside risk potential of 62.94%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 82.19%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

TransMedics Group has a beta of 2.058, which suggesting that the stock is 105.81% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

TransMedics Group quarterly revenues are $108.8M, which are larger than Stereotaxis quarterly revenues of $9.2M. TransMedics Group's net income of $4.2M is higher than Stereotaxis's net income of -$6.2M. Notably, TransMedics Group's price-to-earnings ratio is 66.60x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 5.40x versus 8.27x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.